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Abstract
Many machine learning and pattern classification methods have been applied to the diagnosis of
Alzheimer’s disease (AD) and its prodromal stage, i.e., mild cognitive impairment (MCI).
Recently, rather than predicting categorical variables as in classification, several pattern regression
methods have also been used to estimate continuous clinical variables from brain images.
However, most existing regression methods focus on estimating multiple clinical variables
separately and thus cannot utilize the intrinsic useful correlation information among different
clinical variables. On the other hand, in those regression methods, only a single modality of data
(usually only the structural MRI) is often used, without considering the complementary
information that can be provided by different modalities. In this paper, we propose a general
methodology, namely Multi-Modal Multi-Task (M3T) learning, to jointly predict multiple
variables from multi-modal data. Here, the variables include not only the clinical variables used
for regression but also the categorical variable used for classification, with different tasks
corresponding to prediction of different variables. Specifically, our method contains two key
components, i.e., (1) a multi-task feature selection which selects the common subset of relevant
features for multiple variables from each modality, and (2) a multi-modal support vector machine
which fuses the above-selected features from all modalities to predict multiple (regression and
classification) variables. To validate our method, we perform two sets of experiments on ADNI
baseline MRI, FDG-PET, and cerebrospinal fluid (CSF) data from 45 AD patients, 91 MCI
patients, and 50 healthy controls (HC). In the first set of experiments, we estimate two clinical
variables such as Mini Mental State Examination (MMSE) and Alzheimer’s Disease Assessment
Scale - Cognitive Subscale (ADAS-Cog), as well as one categorical variable (with value of ‘AD’,
‘MCI’ or ‘HC’), from the baseline MRI, FDG-PET, and CSF data. In the second set of
experiments, we predict the 2-year changes of MMSE and ADAS-Cog scores and also the
conversion of MCI to AD from the baseline MRI, FDG-PET, and CSF data. The results on both
sets of experiments demonstrate that our proposed M3T learning scheme can achieve better
performance on both regression and classification tasks than the conventional learning methods.
1Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
(www.loni.ucla.edu/ADNI). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or
provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at:
www.loni.ucla.edu\ADNI\Collaboration\ADNI_Authorship_list.pdf.
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia diagnosed in people over
65 years of age. It is reported that there are 26.6 million AD sufferers worldwide, and 1 in
85 people will be affected by 2050 (Ron et al., 2007). Thus, accurate diagnosis of AD and
especially its early stage, i.e., mild cognitive impairment (MCI), is very important for timely
therapy and possible delay of the disease. Over the past decade, many machine learning and
pattern classification methods have been used for early diagnosis of AD and MCI based on
different modalities of biomarkers, e.g., the structural brain atrophy measured by magnetic
resonance imaging (MRI) (de Leon et al., 2007; Du et al., 2007; Fjell et al., 2010; McEvoy
et al., 2009), metabolic alterations in the brain measured by fluorodeoxyglucose positron
emission tomography (FDG-PET) (De Santi et al., 2001; Morris et al., 2001), and
pathological amyloid depositions measured through cerebrospinal fluid (CSF) (Bouwman et
al., 2007b; Fjell et al., 2010; Mattsson et al., 2009; Shaw et al., 2009), etc. In all these
methods, classification models are learned from training subjects to predict categorical
classification variable (i.e., class label) on test subjects.
Recently, rather than predicting categorical variables as in classification, several studies
begin to estimate continuous clinical variables from brain images (Duchesne et al., 2009;
Duchesne et al., 2005; Fan et al., 2010; Stonnington et al., 2010; Wang et al., 2010). This
kind of research is important because it can help evaluate the stage of AD pathology and
predict future progression. Different from classification that classifies a subject into binary
or multiple categories, regression needs to estimate continuous values and are thus more
challenging. In the literature, a number of regression methods have been used for estimating
clinical variables based on neuroimaging data. For example, linear regression models were
used to estimate the 1-year Mini Mental State Examination (MMSE) changes from structural
MR brain images (Duchesne et al., 2009; Duchesne et al., 2005). High-dimensional kernel-
based regression method, i.e., Relevance Vector Machine (RVM), were also used to estimate
clinical variables, including MMSE and Alzheimer’s Disease Assessment Scale - Cognitive
Subscale (ADAS-Cog), from structural MR brain images (Fan et al., 2010; Stonnington et
al., 2010; Wang et al., 2010). Besides clinical variables, regression methods have also been
used for estimating age of individual subject from MR brain images (Ashburner, 2007;
Franke et al., 2010).
In the practical diagnosis of AD, multiple clinical variables are generally acquired, e.g.,
MMSE and ADAS-Cog, etc. Specifically, MMSE is used to examine the orientation to time
and place, the immediate and delayed recall of three words, the attention and calculations,
language, and visuoconstructional functions (Folstein et al., 1975), while ADAS-Cog is a
global measure encompassing the core symptoms of AD (Rosen et al., 1984). It is known
that there exist inherent correlations among multiple clinical variables of a subject, since the
underlying pathology is the same (Fan et al., 2010; Stonnington et al., 2010). However, most
existing regression methods model different clinical variables separately, without
considering their inherent correlations that may be useful for robust and accurate estimation
of clinical variables from brain images. Moreover, to our knowledge, none of the existing
regression methods used for estimating clinical variables ever exploit the class labels which
are often available in the training subjects and are helpful to aid the accurate estimation of
regression variables, and vice versa.
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On the other hand, although multi-modal data are often acquired for AD diagnosis, e.g.,
MRI, PET, and CSF biomarkers, nearly all existing regression methods developed for
estimation of clinical variables were based only on one imaging modality, i.e., mostly on the
structural MRI. Recent studies have indicated that the biomarkers from different modalities
provide complementary information, which is very useful for AD diagnosis (Fjell et al.,
2010; Landau et al., 2010; Walhovd et al., 2010b). More recently, a number of research
works have used multi-modal data for AD or MCI classification and obtained the improved
performance compared with the methods based only on single-modal data (Fan et al., 2008;
Hinrichs et al., 2011; Vemuri et al., 2009; Walhovd et al., 2010a; Zhang et al., 2011).
However, to the best of our knowledge, the same type of study in imaging-based regression,
i.e., estimation of clinical variables from multi-modal data, was not investigated previously.
Inspired by the above problems, in this paper, we propose a general methodology, namely
Multi-Modal Multi-Task (M3T) learning, to jointly predict multiple variables from multi-
modal data. Here, the variables include not only the continuous clinical variables for
regression (MMSE, ADAS-Cog) but also the categorical variable for classification (i.e.,
class label). We treat the estimation of different regression or classification variables as
different tasks, and use a multi-task learning method (Argyriou et al., 2008; Obozinski et al.,
2006) developed in the machine learning community for joint regression and classification
learning. Specifically, at first, we assume that the related tasks share a common relevant
feature subset but with a varying amount of influence on each task, and thus adopt a multi-
task feature selection method to obtain a common feature subset for different tasks
simultaneously. Then, we use a multi-modal support vector machine (SVM) method to fuse
the above-selected features from each modality to estimate multiple regression and
classification variables.
We validate our method on two sets of experiments. In the first set of experiments, we
estimate two regression variables (MMSE and ADAS-Cog) and one classification variable
(with value of ‘AD’, ‘MCI’ or ‘HC’) from the baseline MRI, PET, and CSF data. In the
second of experiment, we predict the 2-year changes of MMSE and ADAS-Cog scores and
also the conversion of MCI to AD from the baseline MRI, PET, and CSF data. We
hypothesize that the joint estimation or prediction of multiple regression and classification
variables would perform better than estimating or predicting each individual variable
separately, and that the use of multi-modal data (MRI, PET and CSF) would perform better
on joint regression and classification than the use of only single-modal data.
Method
The data used in the preparation of this paper were obtained from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu/ADNI). The ADNI was
launched in 2003 by the National Institute on Aging (NIA), the National Institute of
Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration
(FDA), private pharmaceutical companies, and non-profit organizations, as a $60 million, 5-
year public-private partnership. The primary goal of ADNI has been to test whether the
serial MRI, PET, other biological markers, and clinical and neuropsychological assessment
can be combined to measure the progression of MCI and early AD. Determination of
sensitive and specific markers of very early AD progression is intended to aid researchers
and clinicians to develop new treatments and monitor their effectiveness, as well as lessen
the time and cost of clinical trials.
ADNI is the result of efforts of many coinvestigators from a broad range of academic
institutions and private corporations, and subjects have been recruited from over 50 sites
across the U.S. and Canada. The initial goal of ADNI was to recruit 800 adults, aged 55 to
Zhang et al. Page 3













90, to participate in the research – approximately 200 cognitively normal older individuals
to be followed for 3 years, 400 people with MCI to be followed for 3 years, and 200 people
with early AD to be followed for 2 years (see www.adni-info.org for up-to-date
information). The research protocol was approved by each local institutional review board
and written informed consent is obtained from each participant.
Subjects
The ADNI general eligibility criteria are described at www.adni-info.org. Briefly, subjects
are between 55–90 years of age, having a study partner able to provide an independent
evaluation of functioning. Specific psychoactive medications will be excluded. General
inclusion/exclusion criteria are as follows: 1) healthy subjects: MMSE scores between 24–
30, a Clinical Dementia Rating (CDR) of 0, non-depressed, non MCI, and nondemented; 2)
MCI subjects: MMSE scores between 24–30, a memory complaint, having objective
memory loss measured by education adjusted scores on Wechsler Memory Scale Logical
Memory II, a CDR of 0.5, absence of significant levels of impairment in other cognitive
domains, essentially preserved activities of daily living, and an absence of dementia; and 3)
Mild AD: MMSE scores between 20–26, CDR of 0.5 or 1.0, and meets the National Institute
of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association (NINCDS/ADRDA) criteria for probable AD.
In this paper, 186 ADNI subjects with all corresponding baseline MRI, PET, and CSF data
are included. In particular, it contains 45 AD patients, 91 MCI patients (including 43 MCI
converters (MCI-C) and 48 MCI non-converters (MCI-NC)), and 50 healthy controls. Table
1 lists the demographics of all these subjects. Subject IDs are also given in Supplemental
Table 4.
MRI, PET, and CSF
A detailed description on acquiring MRI, PET and CSF data from ADNI as used in this
paper can be found at (Zhang et al., 2011). Briefly, structural MR scans were acquired from
1.5T scanners. Raw Digital Imaging and Communications in Medicine (DICOM) MRI scans
were downloaded from the public ADNI site (www.loni.ucla.edu/ADNI), reviewed for
quality, and automatically corrected for spatial distortion caused by gradient nonlinearity
and B1 field inhomogeneity. PET images were acquired 30–60 minutes post-injection,
averaged, spatially aligned, interpolated to a standard voxel size, intensity normalized, and
smoothed to a common resolution of 8mm full width at half maximum. CSF data were
collected in the morning after an overnight fast using a 20- or 24-gauge spinal needle, frozen
within 1 hour of collection, and transported on dry ice to the ADNI Biomarker Core
laboratory at the University of Pennsylvania Medical Center. In this study, CSF Aβ42, CSF
t-tau and CSF p-tau are used as features.
Image analysis
Image pre-processing is performed for all MR and PET images following the same
procedures as in (Zhang et al., 2011). First, we do anterior commissure (AC) - posterior
commissure (PC) correction on all images, and use the N3 algorithm (Sled et al., 1998) to
correct the intensity inhomogeneity. Next, we do skull-stripping on structural MR images
using both brain surface extractor (BSE) (Shattuck et al., 2001) and brain extraction tool
(BET) (Smith, 2002), followed by manual edition and intensity inhomogeneity correction.
After removal of cerebellum, FAST in the FSL package (Zhang et al., 2001) is used to
segment structural MR images into three different tissues: grey matter (GM), white matter
(WM), and cerebrospinal fluid (CSF). After registration using HAMMER (Shen and
Davatzikos, 2002), we obtain the subject-labeled image based on a template with 93
manually labeled ROIs (Kabani et al., 1998). For each of the 93 ROI regions in the labeled
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MR image, we compute the GM tissue volume of that region as a feature. For PET image,
we first align it to its respective MR image of the same subject using a rigid transformation,
and then compute the average intensity of each ROI in the PET image as a feature.
Therefore, for each subject, we totally obtain 93 features from MRI image, other 93 features
from PET image, and 3 features from CSF biomarkers.
Multi-Modal Multi-Task (M3T) learning
A new learning method, namely Multi-Modal Multi-Task (M3T) learning, is presented here
to simultaneously learn multiple tasks from multi-modal data. Fig. 1 illustrates the new
learning problem with comparison to the existing standard Single-Modal Single-Task
(SMST) learning, Multi-Task learning, and Multi-Modal learning. As can be seen from Fig.
1, in SMST and Multi-Task learning (Fig. 1(a–b)), each subject has only one modality of
data represented as xi, while, in M3T and Multi-Modal learning (Fig. 1(c–d)), each subject
has multiple modalities of data represented as . On the other hand, Fig. 1 also
shows that, in SMST and Multi-Modal learning (Fig. 1(a) and (c)), each subject corresponds
to only one task denoted as ti, while, in M3T and Multi-Task learning (Fig. 1(b) and (d)),
each subject corresponds to multiple tasks denoted as .
Now we can formally define the M3T learning as below. Given N training subjects and each
having M modalities of data, represented as , our
M3T method jointly learns a series of models corresponding to T different tasks denoted as
. It is worth noting that M3T is a general learning
framework, and here we implement it through two successive major steps, i.e., (1) multi-task
feature selection (MTFS) and (2) multi-modal support vector machine (SVM) (for both
regression and classification). Fig. 2 illustrates the flowchart of the proposed M3T method,
where M = 3 modalities of data (e.g., MRI, PET, and CSF) are used for jointly learning
models corresponding to different tasks. Note that, for CSF modality, the original 3
measures (i.e., Aβ42, t-tau, and p-tau) are directly used as features without any feature
selection step.
Multi-task feature selection (MTFS)—For imaging modalities such as MRI and PET,
even after feature extraction, the number of features (extracted from brain regions) may be
still large. Besides, not all features are relevant to the disease under study. So, feature
selection is commonly used for dimensionality reduction, as well as for removal of
irrelevant features. Different from the conventional single-task feature selection, the multi-
task feature selection simultaneously selects a common feature subset relevant to all tasks.
This point is especially important for diagnosis of neurological diseases, since multiple
regression/classification variables are essentially determined by the same underlying
pathology, i.e., the diseased brain regions. Also, simultaneously performing feature selection
for multiple regression/classification variables is very helpful to suppress noises in the
individual variables.
Denote  as the training data matrix on the m-th modality from
N training samples, and  as the response vector on the j-th task
from the same N training samples. Following the method proposed in (Obozinski et al.,
2006), linear models are used to model the multi-task feature selection (MTFS) as below:
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where  is the weight vector for the j-th task on the m-th modality, and x(m) is the m-th
modal data of a certain subject. The weight vectors for all T tasks form a weight matrix
, which can be optimized by the following objective function:
where V(m)|d denotes the d-th row of V(m), D(m) is the dimension of the m-th modal data, and
λ is the regularization coefficient controlling the relative contributions of the two terms.
Note that λ also controls the ‘sparsity’ of the linear models, with the high value
corresponding to more sparse models (i.e., more values in V(m) are zero). It is easy to know
that the above equation reduces to the standard l1-norm regularized optimization problem in
Lasso (Tibshirani, 1996) when there is only one task. In our case, this is a multi-task
learning for the given m-th modal data.
The key point of the above objective function of MTFS is the use of l2-norm for V(m)|d,
which forces the weights corresponding to the d-th feature (of the m-th modal data) across
multiple tasks to be grouped together and tends to select features based on the strength of T
tasks jointly. Note that, because of the characteristic of ‘group sparsity’, the solution of
MTFS results in a weight matrix V(m) whose elements in some rows are all zeros. For
feature selection, we just keep those features with non-zero weights. At present, there are
many algorithms developed to solve MTFS; in this paper we adopt the SLEP toolbox (Liu et
al., 2009), which has been shown very effective on many datasets.
Multi-modal support vector machine—In our previous work (Zhang et al., 2011), the
multi-modal support vector classification (SVC) has been developed for multi-modal
classification of AD and MCI. Following (Zhang et al., 2011), in this paper, we derive the
corresponding multi-modal support vector regression (SVR) algorithm as below. Assume
that we have N training subjects with the corresponding target output {zi ∈ ℝ, i = 1, …, N},
and each subject has M modalities of data with the features selected by the above proposed
method and denoted as . Multi-modal SVR solves the
following primal problem:
Where w(m), ϕ(m), and βm ≥ 0 denote the normal vector of hyperplane, the kernel-induced
mapping function, and the combining weight on the m-th modality, respectively. Here, we
constrain ∑m βm = 1. The parameter b is the offset. Note that ε-insensitive loss function is
used in the above objective function, and ξ and ξ* are the two sets of slack variables.
Similar to the conventional SVR, the dual form of the multi-modal SVR can be represented
as below:
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Where  is the kernel function for the two training
samples on the m-th modality.
For a test sample with the selected features x = {x(1), …, x(m), …, x(M)}, we denote
 as the kernel between each training sample x′i and
the test sample on the m-th modality. Then, the regression function takes the following form:
Similar to the multi-modal SVC (Zhang et al., 2011), the multi-modal SVR can also be
solved with the conventional SVR, e.g., through the LIBSVM toolbox, if we define the
mixed kernel  between multi-modal training samples x′i
and x′j, and  between multimodal training sample x′i and
test sample x. Here, βms are the nonnegative weight parameters used to balance the
contributions of different modalities, and their values are optimized through a coarse-grid
search by cross-validation on the training samples.
After obtaining the common feature subset for all different tasks by MTFS as described
above, we use multi-modal SVM, including multi-modal SVC and multi-modal SVR, to
train the final support vector classification and regression models, respectively. Here, we
train a model for each corresponding variable (task). Specifically, we train support vector
regression models corresponding to the regression variables, and support vector
classification models corresponding to the classification variable, respectively. It is worth
noting that, since we use the common subset of features (learned by MTFS during the
feature selection stage) to train both regression and classification models, our models are
actually performing the multi-modal multi-task learning.
Validation
To evaluate the performance of different methods, we perform two sets of experiments on
186 ADNI baseline MRI, PET, and CSF data, respectively, from 45 AD, 91 MCI (including
43 MCI-C and 48 MCI-NC), and 50 HC. In the first set of experiments (Experiment 1), we
estimate two clinical variables (including MMSE and ADAS-Cog) and one categorical
variable (with class label of ‘AD’, ‘MCI’ or ‘HC’) from the baseline brain data of all 186
subjects. It is worth noting that only the baseline data of MRI, PET, and CSF are used in our
experiments, but, in order to alleviate the effect of noise in the measured clinical scores, we
use the mean clinical score at both baseline and immediate follow-up time points as the
ground truth for each subject. The same strategy has also been adopted in (Wang et al.,
2010). In the second set of experiments (Experiment 2), we predict the 2-year changes of
MMSE and ADAS-Cog scores and the conversion of MCI to AD from the baseline brain
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data of 167 subjects (since 19 subjects do not have the 2-year follow-up MMSE or ADAS-
Cog scores and are thus discarded, as shown in Supplemental Table 4). Also, only the
baseline data of MRI, PET, and CSF are used in the experiment, and the corresponding
ground truths for the two regression tasks are the MMSE and ADAS-Cog changes from
baseline to the 2-year follow-up. For classification task, we will discriminate between MCI-
C and MCI-NC subjects, using the baseline MRI, PET, and CSF data.
We use 10-fold cross validation strategy by computing the Pearson’s correlation coefficient
(for measuring the correlation between the predicted clinical scores and the actual clinical
score in the regression tasks) and the classification accuracy (for measuring the proportion
of subjects correctly classified in the classification task). Specifically, the whole set of
subject samples are equally partitioned into 10 subsets, and each time the subject samples
within one subset are selected as the testing samples and all remaining subject samples in the
other 9 subsets are used for training the SVM models. This process is repeated for 10 times.
It is worth noting that, in Experiment 1, two binary classifiers (i.e., AD vs. HC and MCI vs.
HC, respectively) are built. Specifically, for AD vs. HC classification, we ignore the MCI
subjects at each cross-validation trial and use only the AD and HC subjects. Similarly, for
MCI vs. HC classification, we ignore the AD subjects at each cross-validation trial and use
only the MCI and HC subjects. On the other hand, in Experiment 2, only one binary
classifier (i.e., MCI-C vs. MCI-NC) is built involving only the MCI subjects. In both
experiments, SVM is implemented using LIBSVM toolbox (Chang and Lin, 2001), and
linear kernel is used after normalizing each feature vector with unit norm. For all respective
methods, the values of the parameters (e.g., λ and βm) are determined by performing another
round of cross-validation on the training data. Also, at preprocessing stage, we perform a
common feature normalization step, i.e., subtracting the mean and then dividing the standard
deviation (of all training subjects) for each feature value.
Results
Experiment 1: Estimating clinical stages (MMSE, ADAS-Cog, and class label)
We first estimate the clinical stages, including two regression variables (MMSE and ADAS-
Cog) and one classification variable (i.e., class label with a value of ‘AD’, ‘MCI’ or ‘HC’),
from the baseline MRI, PET, and CSF data. It is worth noting that the original multi-class
classification problem is formulated as two binary classification problems, i.e., AD vs. HC
and MCI vs. HC, as mentioned above. Table 2 shows the performances of the proposed
M3T method, compared with three methods each using individual modality, as well as the
CONCAT method (as detailed below). Specifically, in Table 2, MRI-, PET-, and CSF-based
methods denote the classification results using only the respective individual modality of
data. For MRI-based and PET-based methods, similarly as our M3T method, they contain
two successive steps, i.e., (1) the single-task feature selection method using Lasso
(Tibshirani, 1996), and (2) the standard SVM for both regression and classification. For
CSF-based method, it uses the original 3 features without any further feature selection, and
performs the standard SVM for both regression and classification. Obviously, MRI-, PET-
and CST-based methods all belong to the SMST learning as shown in Fig. 1. For
comparison, we also implement a simple concatenation method (denoted as CONCAT) for
using multi-modal data. In the CONCAT method, we first concatenate 93 features from
MRI, 93 features from PET, and 3 features from CSF into a 189 dimensional vector, and
then perform the same two steps (i.e., Lasso feature selection and SVM regression/
classification) as in MRI-, PET- and CSF-based methods. It is worth noting that the same
experimental settings are used in all five methods as compared in Table 2. Figs. 3–4 further
show the scatter plots of the estimated scores vs. the actual scores by five different methods
for MMSE and ADAS-Cog, respectively.
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As can be seen from Table 2 and Figs. 3–4, our proposed M3T method consistently achieves
better performance than other four methods. Specifically, for estimating MMSE and ADAS-
Cog scores, our method achieves the correlation coefficients of 0.697 and 0.739,
respectively, while the best performance using individual modality is only 0.658 and 0.670
(when using PET), respectively. On the other hand, for AD vs. HC and MCI vs. HC
classification, our method achieves the accuracies of 0.933 and 0.832, respectively, while
the best performance using individual modality is only 0.848 (when using MRI) and 0.797
(when using PET), respectively. Table 2 and Figs. 3–4 also indicate that our proposed M3T
method consistently outperforms the CONCAT method on each performance measure,
although the latter also achieves better performance than three MRI-, PET-, or CSF-based
methods in most cases, because of using multimodal imaging data. However, CSF-based
method always achieves the worst performances in all tasks, and is significantly inferior to
MRI- and PET-based methods in this experiment. Finally, for each group (i.e., AD, MCI or
HC), we compute its average estimated clinical scores using M3T, with respective values of
24.8 (AD), 25.5 (MCI) and 28.1 (HC) for MMSE, and 14.9 (AD), 13.3 (MCI) and 8.3 (HC)
for ADAS-Cog. These results show certain consistency with the actual clinical scores as
shown in Table 1.
We also compare M3T with its two variants, i.e., Multi-Modal (Single-Task) and (Single-
Modal) Multi-Task methods as described in Fig. 1. Briefly, in Multi-Modal (Single-Task)
method, the single-task feature selection method (Lasso) and the multi-modal SVM (for both
regression and classification) are successively performed, while in Multi-Task method, the
multi-task feature selection method (MTFS) and the standard SVM (for both regression and
classification) are successively performed. In addition, we also contain the SMST methods
(MRI-, PET-, or CSF-based) for comparison. Fig. 5 shows the comparison results of those
methods on Experiment 1. It is worth noting that, using only CSF, (Single-Modal) Multi-
Task method is equivalent to SMST since in this case the original CSF measures are directly
used as features without any feature selection step. As can be seen from Fig. 5, our M3T
method consistently outperforms the other three methods: SMST, Multi-Modal (Single-
Task), and (Single-Modal) Multi-Task. Fig. 5 also indicates that, when performing MMSE
regression and AD vs. HC classification using MRI-based or PET-based method, and when
performing ADAS-Cog regression and MCI vs. HC classification using PET-based method,
(Single-Modal) Multi-Task method, which jointly estimates multiple regression/
classification variables, achieves better performance than SMST which estimates each
variable separately. On the other hand, Fig. 5 also shows that Multi-Modal (Single-Task)
method consistently outperforms SMST on both regression and classification, which
validates and further complements the existing conclusion on the advantage of multi-modal
classification using MRI, PET, and CSF data (Zhang et al., 2011). Finally, the t-test (at 95%
significance level) results between M3T and the second best method, i.e., Multi-Modal
(Single-Task) method, show that the former is significantly better than the latter on tasks of
estimating ADAS-Cog score and classifying between MCI and HC.
Experiment 2: Predicting 2-year MMSE and ADAS-Cog changes and MCI conversion
In this experiment, we predict the 2-year changes of MMSE and ADAS-Cog scores and the
conversion of MCI to AD, from the baseline MRI, PET, and CSF data. Here, we have two
regression tasks corresponding to the prediction of the regression variables of MMSE and
ADAS-Cog changes from baseline to 2-year follow-up, respectively, and one classification
task corresponding to prediction of the classification variable of MCI conversion to AD, i.e.,
MCI-C vs. MCI-NC. It is worth noting that as in Experiment 1, only the baseline MRI, PET,
and CSF data are used for all prediction tasks. We use the same subjects as in Experiment 1,
except for 19 subjects without 2-year MMSE or ADAS-Cog scores, thus reducing to totally
167 subjects with 40 AD, 80 MCI (38 MCI-C and 42 MCI-NC), and 47 HC that are finally
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used in Experiment 2. Table 3 shows the performance of the proposed M3T method
compared with three individual-modality based methods and also the CONCAT method,
which are the same methods as those used in Experiment 1. Here, for MCI-C vs. MCI-NC
classification, besides reporting the classification accuracy, we also give other performance
measures including sensitivity (i.e., the proportion of MCI-C subjects correctly classified)
and the specificity (i.e., the proportion of MCI-NC subjects correctly classified). In addition,
we also plot the ROC curves of five different methods for classification between MCI-C and
MCI-NC, as shown in Fig. 6. Here, the individual-modality based methods (using MRI, CSF
or PET) and the CONCAT method are defined in the same way as in Experiment 1.
Table 3 and Fig. 6 show that, as in Experiment 1, M3T also consistently outperform the
individual-modality based methods and the CONCAT method, on both regression and
classification tasks. Specifically, our method achieves the correlation coefficients of 0.511
and 0.531 and the accuracy of 0.739, for predicting the 2-year changes of MMSE and
ADAS-Cog scores and the MCI conversion, respectively, while the best performance of
individual-modality based methods are 0.434 (when using PET), 0.455 (when using MRI),
and 0.639 (when using PET), respectively. In addition, the area under the ROC curve (AUC)
is 0.797 for MCI-C vs. MCI-NC classification with our M3T method, while the best AUC
using the individual-modality based method is 0.70 (when using PET) and the AUC of the
CONCAT method is 0.729. On the other hand, if comparing Table 3 with Table 2, we can
see that there is a significant decline in the corresponding performances. It implies that
predicting future MMSE and ADAS-Cog changes and the MCI conversion is much more
difficult and challenging than estimating the MMSE and ADAS scores and the class labels.
Finally, as in Experiment 1, we compare our M3T method with Multi-Modal (Single-Task),
(Single-Modal) Multi-Task, and SMST (including MRI, CSF or PET) methods, with the
results shown in Fig. 7. As can be seen from Fig. 7, M3T consistently achieves the best
performances among all methods. Fig. 7 also shows that, in all cases except on CSF-based
regression/classification (where no feature selection is performed), (Single-Modal) Multi-
Task method achieves better performance than the corresponding SMST method. On the
other hand, Fig. 7 also indicates that Multi-Modal (Single-Task) method consistently
outperforms the corresponding SMST method in both regression and classification tasks.
These results, respectively, validate the superiorities of Multi-Modal (Single-Task) and
(Single-Modal) Multi-Task methods over SMST method, where both methods improve
performance of SMST from different aspects. By fusing Multi-Modal (Single-Task) and
(Single-Modal) Multi-Task methods together in a unified framework, M3T further improves
the performance. In particular, the t-test (at 95% significance level) results between M3T
and the second best method, i.e., Multi-Modal (Single-Task) method, show that the former is
significantly better than the latter on tasks of predicting 2-year change of MMSE score and
predicting the conversion of MCI to AD.
Group comparisons of multiple variables
To investigate the relationship between multiple regression and classification variables in
Experiment 1 (including MMSE score, ADAS-Cog score, and class label (AD/MCI/HC))
and Experiment 2 (including MMSE change, ADAS-Cog change, and class label (MCI-C/
MCI-NC)), we perform group comparisons on them through the computation of the
correlation between each brain region and each variable across all subjects. Fig. 8 shows the
top 25% brain regions (with their names listed in Supplemental Table 5) that have the
highest correlation with class label (AD/MCI/HC), MMSE and ADAS-Cog scores using
MRI on Experiment 1, where different color represents correlation coefficient. For
comparison, we also list the bottom 25% brain regions with the lowest correlation with class
label, MMSE and ADAS-Cog scores in Supplemental Table 7. As can be seen from Fig. 8,
the selected brain regions with the highest correlations are very consistent across multiple
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variables (i.e., class label, MMSE and ADAS-Cog scores). It implies that that there exist
inherent correlations among multiple variables, since the underlying pathology is the same.
A close observation on Fig. 8 indicates that most of the commonly selected top regions
(from multiple variables), e.g., hippocampal, amygdale and uncus regions, are known to be
related to the AD by many studies using group comparison methods (Chetelat et al., 2002;
Convit et al., 2000; Fox and Schott, 2004; Jack et al., 1999; Misra et al., 2009).
On the other hand, Fig. 9 shows the top 25% brain regions (with their names listed in
Supplemental Table 6) that have the highest correlation with class label (MCI-C/MCI-NC),
MMSE and ADAS-Cog changes using MRI on Experiment 2, where different color again
represents correlation coefficient. For comparison, we also list the bottom 25% brain regions
with the lowest correlation with class label, MMSE and ADAS-Cog changes in
Supplemental Table 8. Fig. 9 indicates that there still exists consistency between the selected
top regions across multiple variables (i.e., class label, MMSE and ADAS-Cog changes), but
it is not as apparent as the regions obtained in Experiment 1. This partly explains the fact
why the lower performance is achieved in predicting the future changes of MMSE and
ADAS-Cog scores and the MCI conversion to AD, compared to estimating the MMSE and
ADAS-Cog scores and the class labels, as shown in Tables 2–3. This is because the tasks of
predicting the future changes of clinical variables and the conversion of MCI to AD are
more challenging than the tasks of estimating clinical variables and class label.
Discussion
In this paper, we have proposed a new Multi-Modal Multi-Task (M3T) learning method
with two successive steps, i.e., multi-task feature selection and multi-modal support vector
machine, to jointly predict multiple regression and classification variables from multi-modal
data. Our proposed method has been validated on 186 baseline subjects from ADNI through
two different sets of experiments. In the first set of experiment, we tested its performance in
jointly estimating the MMSE and ADAS-Cog scores and the class label (AD/MCI/HC) of
subjects, from the baseline MRI, PET, and CSF data. In the second set of experiment, we
tested its performance in jointly predicting the 2-year changes of MMSE and ADAS-Cog
scores and the conversion of MCI to AD, also from the baseline MRI, PET, and CSF data.
Multi-task learning
Multi-task learning is a recent machine learning technique, which learns a set of related
models for predicting multiple related tasks (Argyriou et al., 2008; Obozinski et al., 2006;
Yang et al., 2009). Because multi-task learning uses the commonality among different tasks,
it often leads to a better model than learning the individual tasks separately. In multi-task
learning, one key issue is how to characterize and use the task relatedness among multiple
tasks, with several strategies used in the existing multi-task learning methods: (1) sharing
parameters or prior distributions of the hyperparameters of the models across multiple tasks
(Bi et al., 2008), and 2) sharing a common underlying representation across multiple tasks
(Argyriou et al., 2008; Obozinski et al., 2006; Yang et al., 2009). A few studies have used
multi-tasking learning in medical imaging. For example, multi-task learning, which is based
on sharing common prior distribution in the parameters of different models, is used to detect
different types of clinically related abnormal structures in medical images (Bi et al., 2008).
In another work which is the most related to the current study, a joint Bayesian classifier by
sharing the same hyperparameters for model parameters is used to estimate the MMSE and
ADAS-Cog scores from the baseline MRI data (Fan et al., 2010). In contrast, the multi-task
feature selection method used in this paper belongs to the second scenario, i.e., it assumes
that multiple related tasks share a subset of relevant features and thus select them from a
large common space of features based on group sparsity constraints. Moreover, besides the
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regression tasks on estimating clinical scores including MMSE and ADAS-Cog, our method
also learns classification tasks in a unified multi-task learning framework. Our experimental
results have shown the advantage of jointly estimating multiple regression and classification
variables. Also, it is worth noting that, in (Fan et al., 2010), their method achieved the
correlation coefficients of 0.569 and 0.522 in estimating MMSE and ADAS-Cog scores,
respectively, from the ADNI baseline MRI data of 52 AD, 148 MCI, and 64 HC, which are
inferior to our corresponding results in Table 2.
It is worth noting that feature selection (including both MTFS and Lasso) is performed on
the training data only. Thus, the selected features at each cross-validation trial may be
different. Accordingly, we checked the selected features by MTFS at each cross-validation
trial in Experiment 1, and found that the selected features do vary across different cross-
validation trials. But we also found that some important features such as hippocampal
regions, which are highly relevant to the disease, are always selected in each cross-
validation trial.
Multi-modal classification and regression
In recent studies on AD and MCI, it has been shown that biomarkers from different
modalities contain complementary information for diagnosis of diseases (Apostolova et al.,
2010; de Leon et al., 2007; Fjell et al., 2010; Foster et al., 2007; Landau et al., 2010;
Walhovd et al., 2010b), and thus a lot of works on combining different modalities of
biomarkers have been reported for multi-modal classification (Bouwman et al., 2007a;
Chetelat et al., 2005; Fan et al., 2008; Fellgiebel et al., 2007; Geroldi et al., 2006; Vemuri et
al., 2009; Visser et al., 2002; Walhovd et al., 2010a). Typically in those methods, features
from all different modalities are concatenated into a longer feature vector for the purpose of
multi-modal classification. More recently, multiple-kernel method is used for multi-modal
data fusion and classification, and achieves better performance than the baseline feature
concatenation method (Hinrichs et al., 2011; Zhang et al., 2011).
On the other hand, compared with the abundant works on multi-modal classification, to the
best of our knowledge, there are no previous studies on using multi-modal data for
estimating clinical variables, i.e., using multi-modal regression. Instead, nearly all existing
works on estimating clinical variables use only the structural MRI. However, as shown in
Tables 2–3, in some cases using PET data achieves better performance than using MRI data,
and by further combining MRI, PET, and CSF data, the multi-modal regression methods
always outperform the individual-modality based methods. Also, our experimental results
suggest that, although using only CSF data alone achieves the worst performances in most
cases, it can help build powerful multi-modal regression models when combined with MRI
and PET data. Similar conclusions have also been drawn in the multi-modal classification
(Zhang et al., 2011).
Another general scheme for fusing multi-modal data is the ensemble learning (Zhang et al.,
2011) (denoted as ENSEMBLE in this paper), which trains multiple learners for each
modality and then aggregates them by majority voting (for classification) or averaging (for
regression) at the decision-making level. For comparison, we perform the ENSEMBLE
method on Experiment 1, where the ENSEMBLE method achieves the correlation
coefficients of 0.677 and 0.727 in estimating MMSE and ADAS-Cog scores, respectively,
and the classification accuracies of 0.888 and 0.769 in classifying AD and MCI from HC,
respectively. These results are inferior to the corresponding results of M3T in Table 2. Also,
similar to regression, we found that the ENSEMBLE method cannot achieve satisfactory
results on classification, which implies that the simple majority voting based on the only 3
individual classifiers (from MRI, PET and CSF modalities, respectively) may be not
sufficient for achieving a better ensemble classification on this dataset.
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Our current model adopts (multi-modal) SVM for both regression and classification. For
SVM, a linear kernel is used after normalizing each feature vector with unit norm. The
advantage of using linear kernel is that there is no free parameter to be adjusted. In fact, we
also tried the Gaussian kernel under different values of the kernel width (i.e., sigma) (see
Supplemental Fig. 10). We found that using the linear kernel plus our normalization step can
achieve similar performance as using the Gaussian kernel with the best value of the kernel
width. Moreover, besides SVM, there also exist other models for regression and
classification, e.g., multiple regression, logistic regression, etc (Hastie et al., 2001).
However, our experimental results indicate that these models achieve much poorer
performance than SVM.
Finally, in this paper, for measuring the performance of different methods in regression
tasks, we use the Pearson’s correlation coefficient throughout our experiments. In fact,
besides correlation coefficient, there also exist other performance evaluation metrics, e.g.,
the PRESS statistic which is defined as the sum of squares of the prediction residuals
computed under the Leave-One-Out (LOO) strategy. Here, we compare the performance of
different regression methods on Experiment 1 using a variant of the PRESS metric, i.e.,
PRESS RMSE (root mean square prediction error). Specifically, for estimating MMSE
score, the PRESS RMSE measures of MRI-based, PET-based, CSF-based, CONCAT and
M3T methods are 3.073, 2.669, 3.112, 2.667 and 2.563, respectively. On the other hand, for
estimating ADAS-Cog score, the PRESS RMSE measures of MRI-based, PET-based, CSF-
based, CONCAT and M3T methods are 6.306, 5.966, 6.851, 5.834 and 5.652, respectively.
The above results further show that under the PRESS RMSE metric, our M3T method still
achieves the best performance on both regression tasks, followed by CONCAT and PET-
based methods, which are consistent to our previous results in Table 2 which uses
correlation coefficient as the performance measure.
Prediction of conversion and future decline of MCI
More and more of recent interests in early diagnosis of AD has been moved to identify the
MCI subjects who will progress to clinical AD, i.e., MCI converters (MCI-C), from those
who remain stable, i.e., MCI non-converters (MCI-NC) (Davatzikos et al., 2010; Leung et
al., 2010; Misra et al., 2009). Although our method was not specifically aiming for
prediction of MCI to AD, the achieved performances, i.e., an accuracy of 0.739 and an AUC
of 0.797 on 38 MCI-C and 42 MCI-NC, are very comparable to the best results reported in
several recent studies on ADNI. For example, in (Misra et al., 2009), the accuracy between
0.75 and 0.80 and an AUC of 0.77 were reported on 27 MCI-C and 76 MCI-NC using
structural MRI data of ADNI. In (Davatzikos et al., 2010), the maximum accuracy of 0.617
and AUC of 0.734 were reported on 69 MCI-C and 170 MCI-NC using both MRI and CSF
data. In (Leung et al., 2010), the maximum AUC of 0.67 was reported on 86 MCI-C and 128
MCI-NC using the hippocampal atrophy rates calculated by the boundary shift integral
within ROIs.
On the other hand, a few recent studies also investigated the problem of predicting future
cognitively decline of MCI subjects. For example, a study based on group comparison on 85
MCI from ADNI in (Landau et al., 2010) indicated that CSF and PET could predict
longitudinal cognitive decline. In (Wang et al., 2010), a Bagging relevant vector machine
(RVM) was adopted to predict the future decline of MMSE score from baseline MRI data
and a correlation coefficient of 0.537 was achieved on 16 MCI-C, 5 MCI-NC, and 5 AD. In
contrast, our method achieved the correlation coefficients of 0.511 and 0.531 on 38 MCI-C
and 42 MCI-NC, as well as 40 AD and 47 HC, which are comparable to the result in (Wang
et al., 2010). Finally, in (Duchesne et al., 2009), a principal component analysis (PCA)
based model is used on MRI data of 49 MCI (including 20 MCI-C and 29 MCI-NC) to
predict the one-year change in MMSE score, and a correlation coefficient of 0.31 was
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reported. This low correlation coefficient result indicated that it is more difficult to predict
one-year changes than two-year changes, since the MCI converters (who convert to AD after
two years) had not progress to AD completely after one year and thus the corresponding
measured cognitive scores did not accurately reflect the underlying pathological changes in
brain regions.
Limitations
The current study is limited by several factors as below. First, the proposed method is based
on multi-modal data, i.e., MRI, PET, and CSF, and thus requires each subject to have the
corresponding modality data, which limits the size of subjects that can be used for study. For
example, there are approximately 800 subjects in ADNI database, while there are only
around 200 subjects having all baseline MRI, PET, and CSF data. Second, besides MRI,
PET, and CSF, there also exist other modalities of data, i.e., APOE. However, since not
every subject has this data and the number of subjects with all modality data (including
APOE) is too small for reasonable learning, the current study does not consider APOE for
multimodal classification and regression. Finally, besides MMSE and ADAS-Cog scores,
there exist other clinical scores in ADNI database. However, due to the similar reasons (i.e.,
not every subject has all clinical scores available), we did not investigate those clinical
variables in the current study, although in principle including more related clinical variables
is not difficult and would further improve the regression/classification performance.
Conclusion
In summary, our experimental results have showed that our proposed Multi-Modal Multi-
Task (M3T) method can effectively perform multiple-tasks learning from multi-modal data.
Specifically, it can effectively estimate the MMSE and ADAS-Cog scores and the
classification label in both AD vs. HC and MCI vs. HC classifications, and can also predict
the 2-year MMSE and ADAS-Cog changes and the classification label in MCI-C vs. MCI-
NC classification. To the best of our knowledge, it made the first investigation on jointly
predicting multiple regression and classification variables from the baseline multi-modal
data. In the future work, we will investigate incomplete multi-modal multi-task learning with
missing values in both modalities and tasks, to increase the number of ADNI subjects that
can be used for training our method. Moreover, we will develop new models which can
iteratively use multi-modal and multi-task information, i.e. using regression/classification
results to guide feature selection, for further improving the final performance. This general
wrapper-like framework can embrace a series of feature selection method, e.g., SVM-RFE
(Guyon et al., 2002) which has been widely used in neuroimaging area. We will extend it for
multi-modal multi-task learning and compare with our current model. Finally, it is
interesting to investigate the integration of the existing domain knowledge in AD research
into our current model, for not only achieving good prediction accuracy but also providing
good interpretability in understanding the biology of AD.
Research Highlights
➢ We jointly predict regression and classification variables from multi-modal
data
➢ Two sets of experiments are performed on baseline MRI, PET, and CSF data
from ADNI
➢ We first estimate MMSE and ADAS-Cog clinical scores and class label (AD/
MCI/HC)
➢ We then predict 2-year change of MMSE and ADAS-Cog scores and MCI
conversion to AD
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➢ Our method achieves better performance on both experiments than
conventional ones
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Illustration of the four different learning frameworks
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Flowchart of the proposed M3T method
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Scatter plots of the estimated MMSE scores vs. the actual scores by five different methods
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Scatter plots of the estimated ADAS-Cog scores vs. the actual scores by five different
methods
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Comparison of performances of four different methods on Experiment 1
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ROC curves of five different methods: MRI-based, PET-based, CSF-based, CONCAT, and
M3T methods, for classification between MCI-C and MCI-NC
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Comparison of performances of four different methods on Experiment 2
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Top 25% brain regions with the highest correlation with class label, MMSE, and ADAS-Cog
on Experiment 1
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Top 25% brain regions with the highest correlation with class label, MMSE change, and
ADAS-Cog change on Experiment 2
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Female/Male 16/29 18/32 15/28 16/32
Age 75.4 ± 7.1 75.3 ± 5.2 75.8 ± 6.8 74.7 ± 7.7
Education 14.9 ± 3.4 15.6 ± 3.2 16.1 ± 2.6 16.1 ± 3.0
MMSE (baseline) 23.8 ± 1.9 29.0 ± 1.2 26.6 ± 1.7 27.5 ± 1.6
MMSE (2 years) 19.3 ± 5.6 29.0 ± 1.3 23.8 ± 3.3 26.9 ± 2.6
ADAS-Cog (baseline) 18.3 ± 6.1 7.3 ± 3.3 12.9 ± 3.9 9.7 ± 4.0
ADAS-Cog (2 years) 27.3 ± 11.7 6.3 ± 3.5 16.1 ± 6.4 11.2 ± 5.7
AD = Alzheimer’s Disease, HC = Healthy Control, MCI = Mild Cognitive Impairment, MCI-C = MCI converter, MCI-NC = MCI non-converter,
MMSE = Mini-Mental State Examination, ADAS-Cog = Alzheimer’s Disease Assessment Scale - Cognitive Subscale
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Table 2
Comparison of performances of five different methods on Experiment 1. The reported values are the
correlation coefficient (for MMSE and ADAS-Cog regression) and accuracy (for AD vs. HC and MCI vs. HC
classification), averaged on 10-fold tests (with standard deviation also reported).
Methods
Correlation coefficient Classification accuracy
MMSE ADAS-Cog AD vs. HC MCI vs. HC
MRI-based 0.504 ± 0.038 0.609 ± 0.014 0.848 ± 0.026 0.739 ± 0.028
PET-based 0.658 ± 0.027 0.670 ± 0.018 0.845 ± 0.035 0.797 ± 0.023
CSF-based 0.465 ± 0.019 0.474 ± 0.013 0.805 ± 0.022 0.536 ± 0.044
CONCAT 0.658 ± 0.023 0.695 ± 0.011 0.920 ± 0.033 0.800 ± 0.024
Proposed M3T 0.697 ± 0.022 0.739 ± 0.012 0.933 ± 0.022 0.832 ± 0.015
AD = Alzheimer’s Disease, HC = Healthy Control, MCI = Mild Cognitive Impairment, MMSE = Mini-Mental State Examination, ADAS-Cog =
Alzheimer’s Disease Assessment Scale - Cognitive Subscale
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